Clinical Trial

Dopaminergic Therapy for Anhedonia - 2

Study acronym: DTA-2
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this 8-week, double-blind, placebo-controlled, study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Seventy male and female participants with depression, between 25-55 years of age, with higher levels of inflammation and anhedonia will be randomized to receive L-DOPA or matched placebo over 8 weeks. Participants will complete lab tests, medical and psychiatric assessments, motivation and motor tasks, and MRI scans as part of the study. The total length of participation is approximately 10 to 12 weeks.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-04; most recent amendment 2026-01-26.
Status change: Not Yet Recruiting → Recruiting 2024-01-08
Trial Details
NCT Number NCT06075771
Lead Sponsor Emory University
Collaborators: National Institute of Mental Health (NIMH)
Conditions Anhedonia, Depression
Enrollment 70 participants
Start Date 2023-11-21
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-28